Holen Sie sich die Stockscreener-App
15.52
6.37%
0.93
Schlusskurs vom Vortag:
$14.59
Offen:
$14.49
24-Stunden-Volumen:
1.50M
Relative Volume:
1.17
Marktkapitalisierung:
$891.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.79M
KGV:
-19.93
EPS:
-0.7789
Netto-Cashflow:
$-53.49M
1W Leistung:
+6.52%
1M Leistung:
+23.57%
6M Leistung:
+113.19%
1J Leistung:
+566.09%
1-Tages-Spanne:
$14.28
$15.96
1-Wochen-Bereich:
$13.09
$15.96
52-Wochen-Spanne:
$1.54
$18.33
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
15.52 | 977.57M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Mizuho | Outperform |
| 2026-03-24 | Eingeleitet | B. Riley Securities | Buy |
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-03-05 | Eingeleitet | Wedbush | Outperform |
| 2026-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Climb Bio's (CLYM) Outperform Rating Reiterated at Wedbush - MarketBeat
Climb Bio (NASDAQ:CLYM) Hits New 52-Week HighShould You Buy? - MarketBeat
Is Climb Bio’s (CLYM) Mixed Loss Trends Revealing a Shift in Its Investment Story? - simplywall.st
Do Climb Bio’s (CLYM) Mixed Loss Trends Reveal a Shifting Path to Sustainable Scale? - Yahoo Finance
Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYM - MarketBeat
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Climb Bio Collaborator Beijing Mabworks Begins Phase 2 Trial Dosing for IgA Nephropathy in China - Kalkine Media
Climb Bio (NASDAQ:CLYM) Shares Up 8.2%Still a Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - cnn.com
Climb Bio Advances Phase 2 Renal Disease Trial - TipRanks
Form 8K Climb Bio Inc For: 14 August By Investing.com - Investing.com Australia
Climb Bio and Mabworks begin dosing in Phase 2 trial for kidney disease in China - Investing.com
CLYM Stock Price, Quote & Chart - ChartMill
CLYM Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 2.36%Management Tone Analysis - vinanet.vn
Climb Bio (NASDAQ:CLYM) Hits New 12-Month HighWhat's Next? - MarketBeat
Renaissance Technologies LLC Lowers Holdings in Climb Bio, Inc. $CLYM - MarketBeat
CLYM Q2 2026 Earnings: Narrower-than-Expected Loss Lifts Investor SentimentEarnings Season Outlook - vinanet.vn
We Think Climb Bio (NASDAQ:CLYM) Can Afford To Drive Business Growth - Moomoo
Climb Bio Inc. (CLYM) Slips 2.14% to $13.7 as Biotech Names Face Renewed PressureRating Change - dars.gov.et
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
RBC Capital Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Climb Bio (NASDAQ:CLYM) Hits New 12-Month High Following Strong Earnings - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $25.00 - MarketBeat
BTIG Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $20 - Moomoo
CLIMB BIO INC : TRUIST SECURITIES RAISES TARGET PRICE TO $25 FROM $17 - Bitget
Climb Bio, Inc. Stock 12‑Month Price Target Raised to $21.93, Implies 76% Upside - TradingView
Climb Bio Advances Budoprutug Lupus Trial, Keeping Investors Tuned to Early-Stage Data - TipRanks
Climb Bio Releases Q2 2026 Financial Results - AlphaStreet
Climb Bio Reports Q2 2026 Financial Results and Pipeline Updates in Nasdaq 10-Q Filing - Kalkine Media
Climb Bio, Inc. Q2 2026: Net loss $(13.5M), EPS $(0.18) — 10-Q Summary - TradingView
CLYM: $239.2M cash, $13.5M Q2 net loss, and $103.4M raised to fund clinical pipeline into 2028 - TradingView
Climb Bio (Nasdaq: CLYM) raises $103M, extends cash runway into 2028 - Stock Titan
Climb Bio reports Q2 2026: $239.2M cash, net loss $13.5M; advances CLYM116 and budoprutug programs - TradingView
CLYM: Advanced clinical pipeline and secured $239M cash, extending runway into 2028 - TradingView
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Climb Bio Q2 net loss widens on pipeline advancement - TradingView
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Climb Bio (CLYM) Projected to Post Earnings on Tuesday - MarketBeat
Climb Bio (NASDAQ:CLYM) Rating Increased to Moderate Buy at Royal Bank Of Canada - MarketBeat
CLIMB BIO INC : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $23 - Bitget
RBC Capital Initiates Climb Bio at Outperform With $23 Price Target - marketscreener.com
Climb Bio (NASDAQ:CLYM) Stock Price Down 4.2%Here's What Happened - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Climb Bio’s Budoprutug Trial Completion Sets Stage for Next Investor Catalyst - TipRanks
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesBanking Earnings Report - dars.gov.et
ADAR1 Capital Management LLC Sells 834,813 Shares of Climb Bio, Inc. $CLYM - MarketBeat
Climb Bio Inc (CLYM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Climb Bio Builds Momentum With Late-2026 Data Readouts; Wedbush Sets $20 Target - RTTNews
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade - MarketBeat
CLYM Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):